The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / September / A Dual Approach for Pterygium Removal
Anterior Segment Cornea Opinions

A Dual Approach for Pterygium Removal

Optimizing pterygium removal with conjunctival autograft and amniotic membrane graft

By Himani Goyal 9/7/2026 3 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Topic Commentary

Clinical Report: A Dual Approach for Pterygium Removal

Background

Pterygium is a prevalent ocular surface disorder characterized by abnormal conjunctival tissue growth onto the cornea, often exacerbated by UV exposure. Surgical excision is the definitive treatment, but recurrence remains a significant concern, necessitating effective surgical techniques.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • The pooled global prevalence of pterygia is approximately 10%, with higher rates in equatorial regions.
  • Recurrence rates after pterygium excision can be as high as 18%, with demographic factors influencing risk.
  • The bare sclera method has high recurrence rates, with some studies reporting up to 89%.
  • The combined CAG and AMG technique has demonstrated recurrence rates of around 1% and excellent cosmetic outcomes in nearly 90% of patients.
  • Patients with glaucoma or double pterygium may require alternative surgical strategies due to potential complications.

Clinical Implications

Surgeons should consider patient-specific factors, such as glaucoma or double pterygium, when planning surgical interventions.

Conclusion

Further research may help refine these techniques and identify optimal patient profiles for each surgical strategy.

Related Resources & Content

  1. Ophthalmology Management, Tackling Pterygium, 2021 -- Risk factors for development and recurrence
  2. Ophthalmology Management, Effective Treatment of Pterygium, 2025 -- Surgical outcomes and management
  3. Pterygium - College of Optometrists, 2026 -- Clinical management guidelines
  4. Pterygium - EyeWiki, 2026 -- Surgical consensus and management strategies
  5. Ophthalmology Management — Effective Treatment of Pterygium
  6. Corneal Physician — The Utility of Pre-Descemet’s Endothelial Keratoplasty
  7. Pterygium - College of Optometrists
  8. Pterygium - EyeWiki
  9. Conjunctival Autograft Fixation in Primary Pterygium Surgery: A Network Meta-Analysis of Randomized Trials - PubMed

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: